Vitro Biopharma Launches New Stem Cell Products to Accelerate Bone Growth

GOLDEN, Colo., Jan. 22, 2013 (GLOBE NEWSWIRE) -- Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced the launch of a series of products with application to accelerated bone growth, fracture healing and development of new osteoporosis drugs. The new products are osteoblasts derived from human adult stem cells known as mesenchymal stem cells (MSCs). These cells lead to bone growth and function to maintain bone density and in the recovery from bone fractures. Osteoporosis, a disease characterized by reduction in bone density is thought to result from decreased osteoblast production by MSCs; bone growth necessary for repair of bone fractures also depends on osteoblasts. The new products include native and labeled MSC-derived human osteoblasts in various formats including fluorescent and magnetic cells for use in different imaging methods. For example, magnetic osteoblast cells labeled with super paramagnetic iron oxide (SPIO) may be used for in-vivo imaging of osteoblasts using magnetic resonance imaging (MRI) a common clinical imaging procedure. The availability of native and multiply-labeled osteoblasts provides numerous options to conduct in-vitro high throughput screening cell assays and to coordinate these studies with in-vivo studies.

Back to news